- LifeNet Health LifeSciences: Your New Partner in Drug Discovery and DevelopmentJun
Ed LeCluyse, PhD., explains how LifeNet Health LifeSciences' unique, vertically integrated process has raised the bar for quality standards and enables access to high quality human tissues and cells for research.
Duration:1 hour with live Q&A
- Learn how LifeSciences' recovery program can improve the success of your target identification decision-making process
- Discovery how human primary cells from our advanced tissue processing and cell isolation techniques will enhance your test results for drug metabolism, enzyme induction and hepatotoxicity assays
- Explore how our refined cell culture techniques and novel platforms can provide more accurate and predictive data for candidate selection
Browse our collection of previously recorded webinars
- Understanding Primary Human Hepatocyte Characterization Data
Hear Dr. Ed LeCluyse from LifeNet Health LifeSciences describe the importance of using data to identify the right hepatocyte lots for your specific applications and provides insight on emerging trends in hepatocyte characterization.
- Human Hepatocyte Tri-Culture System: A Convenient 3-in-1 Model for In Vitro Hepatic Assays
Dr. Ed LeCluyse describes the convenient all-human hepatocyte tri-culture model, highlighting improvements in hepatocyte performance compared to traditional monoculture.
- Development of an In Vitro Human Thyroid Microtissue Model
Dr. Chad Deisenroth from the U.S. Environmental Protection Agency Center for Computational Toxicology and Exposure presents a novel in vitro 3D human thyroid microtissue model as a new approach for candidate screening that holds both phenotypic and regulatory relevance.
- Human Liver Non-Parenchymal Cells: Award Winning Actors in Liver Disease
Learn about the role liver non-parenchymal cells (NPCs) play in NASH and liver fibrosis, liver toxicity and drug-induced liver injury (DILI), and how high-quality NPCs are necessary for recapitulating in vivo cell-cell interactions.
- Biospecimens for Research: Accelerating Access and Ensuring Quality
Only LifeNet Health LifeSciences controls every step of every tissues journey from donor to lab while serving researchers needs from early-stage discovery to pre-clinical drug-safety evaluation.
- 3D Models of Microtumors – A New Predictive Tool?
Dr. Chris Willey of University of Alabama at Birmingham’s Departments of Radiation Oncology shares how 3D human microtumors are being established as a human-based diagnostic screening method to optimize chemotherapeutic regimens.
- Accelerating Drug Discovery and Development with Primary Human Hepatocytes
Join us as Dr. Ed LeCluyse reveals how primary human hepatocytes can:
- Fast forward your target identification
- Be applied in drug metabolism and pharmacokinetics
- Improve high content screening
- Utilizing Human Hepatocyte Genotyping Data to Optimize Experimental Design
Dr. Mary Jane Cunningham explains how genotyping of primary human hepatocytes may be essential to your experimental design and how knowing the donor’s genotype could help with stratifying hepatocyte lots used in drug discovery and development assays.
Learn the basics of genotyping and pharmacogenetics
Discover how genotypes relate to the metabolism of Cytochrome P450 isozymes and Phase II molecules
Explore how genotypes for these enzymes can be used in experimental design planning
- Biospecimen Research on Earth and in Space: A Model for Human Osteoarthritis in the Space Shuttle
Join us as guest speaker, Dr. Alan Grodzinsky, Professor of Biology, Electrical, and Mechanical Engineering at Massachusetts Institute of Technology, shares exciting details of his research on osteoarthritis on Earth and in space.
- Considerations for Tissue Donation Authorization - the GTEx Case Study
The Genotyping-Tissue Expression Project (GTEx) launched in 2010 by the National Institutes of Health and included the characterization of genetic associations across 49 tissues from over 800 postmortem donors. Laura Siminoff, PhD, Dean at the College of Public Health at Temple University, was a key contributor in GTEx, where she evaluated best practices for communicating and obtaining authorization from donor families.
Join us as Dr. Siminoff describes:
- Recommendations vs. requirements for authorizing tissue donation
- Essential communication when obtaining consent from donor families
- How tissue donation and research authorization was used for the GTEx project
- All Human Hepatic Tri-Culture System: Switching Gears to High-Throughput Compatibility
Dr. Jessica Weaver, Research and Product Development Scientist at LifeNet Health, will reveal the latest development with our all-human hepatic Tri-Culture system.
Key features of the model that will be explored:
- Resemblance to native, human liver architecture
- Maintenance of hepatocyte phenotype and functionality for at least 2 weeks
- New 96-well compatible design amenable to high-throughput screening and robotics applications
- Cryopreserved Primary Human Thyrocytes for Thyroid Disruptive Chemical Screening
Join LifeNet Health R&D Scientist Eda Rogers, PhD as she shares details of how she and other LifeNet Health LifeSciences scientists have isolated, cryopreserved, and characterized primary human thyrocytes.
Our study shows that these cells:
- Consistently formed 3D thyroid microtissues
- Retained thyroid specific protein expression
- Could represent a valuable tool for evaluating thyroid disruption
- To the Moon and Back! Unique Biospecimen Management
Dr. Scott Jewel and Dr. Galen Hostetter, both of the Van Andel Research Institute, will share their best practices for the management and use of biospecimens, specifically around the identification of variables on biospecimen quality and processing that can directly impact research results.
- Discover how specimens are managed to maintain biospecimen integrity and quality
- Learn how tumor and non-tumor regions can be isolated and analyzed
- Explore alternative procedures used to enrich for target nucleic acid isolation
- Human Liver Non-Parenchymal Cells: Key "Actors" in Liver Disease
Ed LeCluyse, PhD., describes how liver non-parenchymal cells (NPCs), including stellate, Kupffer, and liver endothelial cells, play a roll in the progression of liver toxicity and disease.
- Discover how these human NPCs "role play" with human hepatocytes in the onset and progression of NASH and liver fibrosis
- Learn how high-quality and well-characterized human NPCs are necessary to have an accurate in vitro picture of cell-cell interactions
- Explore how NPCs "act" in liver toxicity and Drug-Induced Liver Injury (DILI)